- Home
- SBGI vs APMD Comparison
SBGI vs APMD Comparison
Compare SBGI & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBGI | APMD |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2023 | 2026 |
Fundamental Metrics
Financial Performance| Metric | SBGI | APMD |
|---|---|---|
| Price | $13.79 | $26.51 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 487.8K | 380.2K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,169,000,000.00 | N/A |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.46 | $20.02 |
| 52 Week High | $17.88 | $35.29 |
Technical Indicators
Market Signals| Indicator | SBGI | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 48.96 |
| Support Level | $13.13 | $23.98 |
| Resistance Level | $14.48 | $30.34 |
| Average True Range (ATR) | 0.45 | 3.37 |
| MACD | -0.05 | -0.40 |
| Stochastic Oscillator | 1.40 | 10.81 |
Price Performance
Historical ComparisonAbout SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay TV distributors.
About APMD Apnimed Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).